Physician profile
Kylene E Botts
NPI 1609030816
$4,686.17
in general payments reported to CMS, 2019-2025
28 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $1,471 · 2023: $1,095 · 2024: $905 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.55 |
| Education | $134.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $966.30 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Boston Scientific Corporation | $477.07 | 2021-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $364.97 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $340.01 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $332.44 | 2023-2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $317.46 | 2021-2023 | |
| Amgen INC. | $292.15 | 2021-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $243.63 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.55 | 2021-2024 | |
| Esperion Therapeutics, INC. | $163.20 | 2021-2024 | Nexletol |
| Pfizer INC. | $140.16 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $129.97 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $127.23 | 2022 | |
| Merck Sharp & Dohme LLC | $120.15 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.16 | 2021-2023 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $73.64 | 2021-2023 | Farxiga |
| Atricure, INC. | $69.63 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $49.91 | 2023-2024 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $33.05 | 2022-2024 | Eliquis |
| Irhythm Technologies, INC. | $32.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.01 | 2021 | |
| Inspire Medical Systems, INC. | $27.33 | 2023 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $25.65 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $18.85 | 2023 | |
| Edwards Lifesciences Corporation | $17.66 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Regeneron Healthcare Solutions, INC. | $17.51 | 2022 | |
| Daiichi Sankyo INC. | $14.32 | 2023 | Injectafer |
| Itamar Medical INC | $10.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylene Botts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.